Home/Indications/Vulvar and Vaginal Atrophy

Vulvar and Vaginal Atrophy

2 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Market Leaders

Treatments by Mechanism

Top 1 mechanisms across 1 industry trials with a known mechanism of action.

See full pipeline →

Estrogen

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

11 industry-sponsored trials across 11 sponsors

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Stratpharma AG	—	—	RECRUITING	2026-04	NCT07346287

Showing 6 of 6 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Prasco LLC	Estrace® Cream	—	COMPLETED	2018-03-15	NCT03332303
Actavis Inc.	Generic Estradiol Vaginal Cream USP, 0.01%	—	COMPLETED	2017-02-15	NCT03294538
Alvogen Pine Brook LLC	Estradiol	Estrogen [EPC]	COMPLETED	2016-12	NCT02995694
Glenmark Pharmaceuticals Ltd. India	Estradiol Vaginal Tablets 10 mcg (Glenmark)	—	COMPLETED	2016-09-21	NCT02668796
Mylan Pharmaceuticals Inc	Estradiol Vaginal Cream, 0.01%	—	COMPLETED	2014-12	NCT02195986
Amneal Pharmaceuticals, LLC	Estradiol Vaginal Tablets 10 mcg	—	COMPLETED	2012-09	NCT01779947

Showing 2 of 2 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Egymedicalpedia	Zinc	—	COMPLETED	2022-12-01	NCT05453227
Izun Pharma Ltd	IZN-6NVS Cream	—	COMPLETED	2016-12	NCT02313545

Showing 2 of 2 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Medinova AG	Estriol 0.03 mg, lyophylized lactobacillus	—	COMPLETED	2012-07	NCT01370551
Novo Nordisk	estradiol, 25 mcg	—	COMPLETED	2010-05	NCT01085877

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Vulvar and Vaginal Atrophy

ER (Estrogen Receptor) (27)

Novel Drugs by Company (New molecular entities)

MILLICENT 1 drug

INTRAROSA

PRASTERONE

NDA 2016

MILLICENT MFG PR 1 drug

FEMRING

ESTRADIOL ACETATE

NDA 2003

Reformulations (10 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.